SCHEMBL5617201

SCHEMBL5617201

CCOC(=O)C(C)=Cc1ccc(O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.57
MAPT P10636 7/20 0.57
MEN1 O00255 6/20 0.57
LMNA P02545 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
S1PR4 O95977 1/20 0.57
S1PR1 P21453 1/20 0.57
MAPK1 P28482 1/20 0.57
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
CA7 P43166 2/20 0.54
CA9 Q16790 2/20 0.54
CA14 Q9ULX7 2/20 0.54
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
KDM4E B2RXH2 5/20 0.50
ALDH1A1 P00352 5/20 0.50
MIF P14174 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12035802 1.00 KMT2A (0.57) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL3609468 0.88 MAPT (0.58) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL3609471 0.88 MAPT (0.58) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL5606791 0.87 ESR1 (0.51) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL7651650 0.86 KMT2A (0.76) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL7030290 0.86 KMT2A (0.76) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL321922 0.86 MAPT (0.57) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL10885404 0.86 MAPT (0.57) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL10564181 0.86 MAPT (0.57) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL14358911 0.86 MAPT (0.57) KMT2AMAPTMEN1LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110088209-B Layered substance-containing liquid and method for producing same 株式会社ADEKA 2023-01-31 CN disclosed
US-20070142472-A1 Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids TAKASAGO INTERNATIONAL CORPORATION (JP) 2007-06-21 US disclosed
EP-1687250-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS Takasago International Corporation (JP) 2006-08-09 EP disclosed
WO-2005051882-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS TAKASAGO INTERNATIONAL CORPORATION (JP) 2005-06-09 WO disclosed
US-6319650-B1 PROVIDING UNCURED FILM OF POLY(4-HYDROXYPHENYLETHYL METHACRYLATE PHENOLIC FUNCTIONAL RESIN, GLYCOLURIL DERIVATIVE, PHOTOACID GENERATOR ON SUBSTRATE; IMAGEWISE EXPOSING TO ULTRAVIOLET RADIATION, DEVELOPING PHOTORESIST INTERNATIONAL BUSINESS MACHINES CORPORATION 2001-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142472-A1 Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids ALDH1A2, ALDH1A3, GRHPR KMT2A 3996/4885MAPT 4570/4885MEN1 3424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.